Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rifaximin SSD · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Rifaximin SSD-40mg IR | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Rifaximin SSD | DRUG | Rifaximin Solid Soluble Dispersion Immediate Release Twice Daily |
| Placebo | DRUG | Placebo Twice Daily |
Key Inclusion Criteria: * Diagnosis of liver cirrhosis with medically controlled ascites (\>30 days) not requiring therapeutic paracentesis (could have had paracentesis in the past). * Conn (West Haven Criteria) score of \< 2. * Mini-Mental State Examination (MMSE) score \> 24 at screening. * ≥ 18 ...
Rifaximin SSD is an investigational small molecule being studied for Hepatic Encephalopathy, a complication of cirrhosis. It is being evaluated for its ability to delay encephalopathy decompensation in patients with cirrhosis. The drug is currently in Phase 3 clinical development and is not yet approved by the FDA.
Rifaximin SSD is a rifamycin antibiotic that targets the gut microbiome. It works by reducing the production of ammonia and other toxins in the gastrointestinal tract, which are believed to contribute to hepatic encephalopathy. By modulating gut bacteria, it aims to prevent the neurological symptoms associated with this condition.
Rifaximin SSD is being developed by Bausch Health Companies Inc., traded on the New York Stock Exchange under the ticker BHC. The company is conducting Phase 3 clinical trials to evaluate the drug's efficacy and safety in patients with cirrhosis who are at risk for hepatic encephalopathy.
Rifaximin SSD is in Phase 3 clinical development. It is currently being evaluated in two active, placebo-controlled, double-blind, randomized trials that are not yet recruiting participants. The drug is investigational and has not received FDA approval for any indication.
Rifaximin SSD is being studied in two Phase 3 clinical trials. NCT05071716 is assessing the drug for delaying encephalopathy decompensation in cirrhosis with 524 participants. NCT05297448 is evaluating the drug for the same purpose in 466 patients. Both trials are active but not recruiting, and are conducted across multiple countries.
Rifaximin SSD is a soluble solid dispersion formulation of rifaximin, an antibiotic used to treat hepatic encephalopathy. While it contains the same active ingredient, the SSD formulation is designed to improve solubility and absorption. It is being studied as a potential new treatment to delay encephalopathy decompensation in cirrhosis.